Cell-cell adhesion regulates Merlin/NF2 interaction with the PAF complex.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 11 09 2020
accepted: 01 07 2021
entrez: 23 8 2021
pubmed: 24 8 2021
medline: 25 11 2021
Statut: epublish

Résumé

The PAF complex (PAFC) coordinates transcription elongation and mRNA processing and its CDC73/parafibromin subunit functions as a tumour suppressor. The NF2/Merlin tumour suppressor functions both at the cell cortex and nucleus and is a key mediator of contact inhibition but the molecular mechanisms remain unclear. In this study we have used affinity proteomics to identify novel Merlin interacting proteins and show that Merlin forms a complex with multiple proteins involved in RNA processing including the PAFC and the CHD1 chromatin remodeller. Tumour-derived inactivating mutations in both Merlin and the CDC73 PAFC subunit mutually disrupt their interaction and growth suppression by Merlin requires CDC73. Merlin interacts with the PAFC in a cell density-dependent manner and we identify a role for FAT cadherins in regulating the Merlin-PAFC interaction. Our results suggest that in addition to its function within the Hippo pathway, Merlin is part of a tumour suppressor network regulated by cell-cell adhesion which coordinates post-initiation steps of the transcription cycle of genes mediating contact inhibition.

Identifiants

pubmed: 34424918
doi: 10.1371/journal.pone.0254697
pii: PONE-D-20-28670
pmc: PMC8382200
doi:

Substances chimiques

CDC73 protein, human 0
Chromatin 0
DNA-Binding Proteins 0
Neurofibromin 2 0
Tumor Suppressor Proteins 0
DNA Helicases EC 3.6.4.-
CHD1 protein, human EC 3.6.4.12

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0254697

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4980-5
pubmed: 21383154
Science. 2002 Jul 5;297(5578):63-4
pubmed: 12098689
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
J Biol Chem. 2011 Aug 12;286(32):28181-91
pubmed: 21680732
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7311-6
pubmed: 20368450
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Cancer Cell. 2011 Apr 12;19(4):527-40
pubmed: 21481793
Dev Cell. 2010 Nov 16;19(5):727-39
pubmed: 21074722
Trends Genet. 2012 Jun;28(6):285-94
pubmed: 22465610
Genes Dev. 2001 Jan 1;15(1):50-65
pubmed: 11156605
Mol Cell Biol. 2005 Jan;25(2):612-20
pubmed: 15632063
Oncogene. 2007 Sep 13;26(42):6176-83
pubmed: 17404568
Development. 2003 Feb;130(4):763-74
pubmed: 12506006
Mol Cell Biol. 2003 May;23(10):3575-82
pubmed: 12724416
Nat Rev Mol Cell Biol. 2015 Mar;16(3):167-77
pubmed: 25693130
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11
pubmed: 25355519
Endocr Relat Cancer. 2010 May 18;17(2):513-24
pubmed: 20304979
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Hum Mol Genet. 2002 Sep 15;11(19):2269-78
pubmed: 12217955
Cell. 2013 Sep 12;154(6):1342-55
pubmed: 24012335
Hum Mutat. 2007 Jan;28(1):1-12
pubmed: 16983642
Cancer Cell. 2014 Jul 14;26(1):48-60
pubmed: 25026211
J Biol Chem. 2009 Mar 13;284(11):6955-65
pubmed: 19131340
PLoS Genet. 2009 Jan;5(1):e1000339
pubmed: 19148280
Anal Biochem. 1992 May 15;203(1):173-9
pubmed: 1524213
Exp Cell Res. 2005 Jul 1;307(1):100-8
pubmed: 15922730
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):11989-94
pubmed: 19574458
Genes Dev. 2009 Dec 1;23(23):2765-77
pubmed: 19952111
Cell. 2010 Feb 19;140(4):491-503
pubmed: 20178742
Genes Dev. 2005 Oct 1;19(19):2265-77
pubmed: 16204178
Science. 2015 Dec 11;350(6266):1383-6
pubmed: 26659056
Hum Mutat. 2010 Mar;31(3):295-307
pubmed: 20052758
Mol Cancer. 2008 Aug 07;7:65
pubmed: 18687124
Nat Genet. 2013 Mar;45(3):253-61
pubmed: 23354438
Oncogene. 2008 Jul 3;27(29):4056-64
pubmed: 18332868
Nat Commun. 2016 Feb 24;7:10822
pubmed: 26905694
Neurosurgery. 1990 Sep;27(3):389-95; discussion 396
pubmed: 2234331
EMBO Rep. 2012 Mar;13(3):204-15
pubmed: 22482125
Oncogene. 2012 Sep 13;31(37):4164-70
pubmed: 22179824
Annu Rev Cancer Biol. 2019 Mar;3(1):167-185
pubmed: 32864546
IUBMB Life. 2010 Mar;62(3):162-9
pubmed: 20014005
Oncogene. 2012 Aug 30;31(35):3939-48
pubmed: 22139082
Anal Chem. 1999 Jul 15;71(14):2871-82
pubmed: 10424174
EMBO J. 2003 Apr 15;22(8):1846-56
pubmed: 12682017
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Genet. 2012 Oct;13(10):720-31
pubmed: 22986266
Cell Rep. 2017 Aug 8;20(6):1435-1447
pubmed: 28793266
Hum Mol Genet. 1994 Jun;3(6):885-91
pubmed: 7951231
Nat Commun. 2014 Nov 12;5:5433
pubmed: 25388829
FEBS Lett. 2014 Aug 19;588(16):2743-52
pubmed: 24726726
Cell. 2015 Aug 27;162(5):1003-15
pubmed: 26279188
Mol Oncol. 2014 Mar;8(2):389-400
pubmed: 24447537
Biochim Biophys Acta. 2010 May-Jun;1799(5-6):379-88
pubmed: 20060942
J Cell Biol. 1996 May;133(4):843-52
pubmed: 8666669
Cell. 2010 Feb 19;140(4):477-90
pubmed: 20178741
PLoS Genet. 2016 Jan 14;12(1):e1005794
pubmed: 26765774
J Virol. 2011 Apr;85(7):3187-202
pubmed: 21270164
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
PLoS Genet. 2013;9(12):e1004029
pubmed: 24385927
Clin Endocrinol (Oxf). 2006 Mar;64(3):299-306
pubmed: 16487440
Nature. 2001 Dec 20-27;414(6866):929-33
pubmed: 11780068
Oncogene. 2007 Nov 29;26(54):7499-507
pubmed: 17599057
Med Res Rev. 2014 Jan;34(1):190-221
pubmed: 23720094
Annu Rev Biochem. 2019 Jun 20;88:577-604
pubmed: 30566373
Mol Cell. 2010 May 14;38(3):439-51
pubmed: 20471949
Nat Commun. 2016 Sep 21;7:12887
pubmed: 27650679
Mol Cell. 2007 Nov 30;28(4):665-76
pubmed: 18042460
Mol Cell Biol. 2015 Oct;35(20):3459-70
pubmed: 26217014
Oncogene. 2005 Feb 10;24(7):1150-8
pubmed: 15580288
Biochim Biophys Acta. 2011 Jan;1809(1):34-45
pubmed: 21081187
Nature. 2010 Jan 21;463(7279):360-3
pubmed: 20054297
Curr Opin Cell Biol. 2012 Oct;24(5):685-94
pubmed: 22835462
Dev Cell. 2010 Jul 20;19(1):27-38
pubmed: 20643348
Oncogene. 2006 Jul 27;25(32):4389-98
pubmed: 16532029

Auteurs

Anne E Roehrig (AE)

UCL Cancer Institute, University College London, London, United Kingdom.

Kristina Klupsch (K)

UCL Cancer Institute, University College London, London, United Kingdom.

Juan A Oses-Prieto (JA)

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, United States of America.

Selim Chaib (S)

UCL Cancer Institute, University College London, London, United Kingdom.

Stephen Henderson (S)

UCL Cancer Institute, University College London, London, United Kingdom.

Warren Emmett (W)

University College London Genetics Institute, London, United Kingdom.

Lucy C Young (LC)

UCL Cancer Institute, University College London, London, United Kingdom.

Silvia Surinova (S)

UCL Cancer Institute, University College London, London, United Kingdom.

Andreas Blees (A)

UCL Cancer Institute, University College London, London, United Kingdom.

Anett Pfeiffer (A)

UCL Cancer Institute, University College London, London, United Kingdom.

Maha Tijani (M)

UCL Cancer Institute, University College London, London, United Kingdom.

Fabian Brunk (F)

UCL Cancer Institute, University College London, London, United Kingdom.

Nicole Hartig (N)

UCL Cancer Institute, University College London, London, United Kingdom.

Marta Muñoz-Alegre (M)

UCL Cancer Institute, University College London, London, United Kingdom.

Alexander Hergovich (A)

UCL Cancer Institute, University College London, London, United Kingdom.

Barbara H Jennings (BH)

UCL Cancer Institute, University College London, London, United Kingdom.

Alma L Burlingame (AL)

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, United States of America.

Pablo Rodriguez-Viciana (P)

UCL Cancer Institute, University College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH